Antidyslipidemics Market Forecast
The antidyslipidemic market is expected to fall to $18 billion in 2018. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiry of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ENHANCE, SEAS and ARBITER 6 HALTS clinical trials.Reasons to Purchase
- Quantify the future size and understand the background of the antidyslipidemic market
- Understand the commercial landscape in terms of new product potential
- Understand the barriers to uptake for novel antidyslipidemics.
Related Reports
- Forecast Insight: Antidyslipidemics - Crestor drives growth before the Lipitor patent cliff hits
- Active Electronically-Scanned Array Radars-Worldwide & Regional Market Forecasts (Systems, TRMs, MMICs) Forecasts to 2015
- Renewable Chemicals Market: Winning Imperatives and market forecast (2010 -2015)
- The Global Bioinformatics Market: Market size, forecasts and company profiles
- Global Sensors Market In Consumer Electronics (2010 - 2015) Market Forecasts By Types & Applications
- Latin American Pharmaceutical Market Outlook To 2014: Policy environment, market analysis, forecasts and growth opportunities
- Turkey Oil Markets, 2010: Investment Opportunities, Market Analysis and Forecasts to 2020
- Turkey Gas Markets, 2010: Investment Opportunities, Market Analysis and Forecasts to 2020
- Ukraine Gas Markets, 2010: Investment Opportunities, Market Analysis and Forecasts to 2020
- Argentina Gas Markets, 2010: Investment Opportunities, Market Analysis and Forecasts to 2020
